{"nctId":"NCT01358266","briefTitle":"Study Assessing Double-masked Uveitis Treatment","startDateStruct":{"date":"2011-05"},"conditions":["Uveitis; Posterior, Disorder"],"count":592,"armGroups":[{"label":"Ophthalmic solution low dose","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: DE-109 44 ug"]},{"label":"Ophthalmic solution medium dose","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: DE-109 440 ug"]},{"label":"Ophthalmic solution high dose","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: DE-109 880 ug"]}],"interventions":[{"name":"DE-109 44 ug","otherNames":["Sirolimus"]},{"name":"DE-109 440 ug","otherNames":["Sirolimus"]},{"name":"DE-109 880 ug","otherNames":["Sirolimus"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Confirmed diagnosis of active uveitis\n* 18 years of age or older\n* Sign informed consent\n* Meet best corrected ETDRS visual acuity\n\nExclusion Criteria:\n\n* Uveitis of infectious etiology\n* Suspected/confirmed central nervous system or ocular lymphoma\n* Primary diagnosis of anterior uveitis\n* Uncontrolled glaucoma\n* Use of topical oculary medication\n* Implanted device\n* Significant ocular disease\n* Lens/media opacities or obscured ocular media\n* Intraocular surgery or treatments\n* Capsulotomy\n* Ocular or periocular infection\n* Pupillary dilation\n* History of herpetic infection\n* Toxoplasmosis or toxoplasmosis scar\n* Ocular malignancy\n* Allergy or hypersensitivity to study drug\n* Participation in other uveitis trial within 30 days\n* Monoclonal antibody treatment or biologic therapy\n* Any systemic condition/infection\n* Immunosuppressive therapy or immunocompromised\n* Malignancy remission\n* Females who are pregnant or lactating and females not using adequate contraceptives","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Primary Endpoint, VH 0 Response, Was Defined as Having a VH Score of 0 at Month 5","description":"At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification\n\nVitreous Haze Scale Description VH score 0 = No inflammation","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"VH 0 or 2-unit Response: Having a Reduction (Improvement) of at Least 2 Units From Baseline in VH Score or a VH Score of 0 at Month 5 (Modified SUN Scale)","description":"At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Step Description 0 No inflammation 0.5+ Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex)\n\n1. Mild blurring of the retinal vessels and optic nerve 1.5+ Optic nerve head and posterior retina view obstruction greater than 1+ but less than 2+\n2. Moderate blurring of the optic nerve head\n3. Marked blurring of the optic nerve head\n4. Optic Nerve head not visible","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"56","spread":null},{"groupId":"OG002","value":"33","spread":null}]}]}]},{"type":"SECONDARY","title":"VH 0 or 0.5+ Response: Having a VH Score of 0 or 0.5+ at Month 5 (Modified SUN Scale)","description":"At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Description VH score 0.5+=Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"104","spread":null},{"groupId":"OG002","value":"70","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"VH 0 Response at Month 6: Having a VH Score of 0 at Month 6 (Modified SUN Scale)","description":"At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification\n\nVitreous Haze Scale Description VH score 0 = No inflammation","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"43","spread":null},{"groupId":"OG002","value":"51","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"VH 0 or 2-unit Response at Month 6: Having a VH Score of 0 or a Decrease (Improvement) of at Least 2 Units From Baseline in VH Score at Month 6 (Modified SUN Scale)","description":"At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Step Description 0 No inflammation 0.5+ Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex)\n\n1. Mild blurring of the retinal vessels and optic nerve 1.5+ Optic nerve head and posterior retina view obstruction greater than 1+ but less than 2+\n2. Moderate blurring of the optic nerve head\n3. Marked blurring of the optic nerve head\n4. Optic Nerve head not visible","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"52","spread":null},{"groupId":"OG002","value":"26","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"VH 0 or 0.5+ Response at Month 6: Having a VH Score of 0 or 0.5+ at Month 6 (Modified SUNscale)","description":"At each visit, slit-lamp biomicroscopy was used to assess VH and opacification. For slit-lamp biomicroscopy, a contact or non-contact lens could have been used. The modified SUN scale for VH was used to measure VH and opacification Vitreous Haze Scale Step Description 0 No inflammation 0.5+ Trace Inflammation (slight blurring of the optic disc margins and or loss of nerve fiber layer reflex)\n\n1. Mild blurring of the retinal vessels and optic nerve 1.5+ Optic nerve head and posterior retina view obstruction greater than 1+ but less than 2+\n2. Moderate blurring of the optic nerve head\n3. Marked blurring of the optic nerve head\n4. Optic Nerve head not visible","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"90","spread":null},{"groupId":"OG002","value":"66","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":41,"n":207},"commonTop":["Intraocular pressure increased","Iridocyclitis","Conjunctival haemorrhage","Uveitis","Eye pain"]}}}